Biocon cancer drug study results in May
Friday, 31 December , 2004, 13:39
Bangalore: Biotech major Biocon's much-talked-about first cancer drug is well on the road to hit the market, with the results of the interim analysis of the antibody expected in May next year.
The clinical evaluations of the drug will be done in April 2005 and the results will be available next month, a Biocon Spokesperson told UNI.
The drug, targeted at head and neck cancer, is currently undergoing advanced second phase clinical trials at the city- based Kidwai Memorial Oncological Institute and is also being tested outside the country. The trials, conducted in Cuba and Canada, have demonstrated complete remission in about 60 per cent of the patients.
On the status of the ongoing trials, the company said 16 patients had been randomised, of which ten were on Biocon Monoclonal antibody (Mab) in combination with standard chemotherapy and radiotherapy.
Biocon Biopharmaceuticals, a joint venture between Biocon and CIMAB, CUBA, developed the drug.
Biocon Chairperson and Managing Director Kiran Mazumdar-Shaw had earlier said the company expected to launch its cancer antibody, Tera HR3, late next year in the country.
Talking during the launch of Insugen, its new insulin product, she said the drug demonstrated very good tumour regression, besides displaying none of the skin reactions common in patients undergoing chemotherapy.
sify.com |
